Clinical trials: Respiratory System
Hypoxia
Accuracy of Owlet Smart Sock Sensor 3rd Generation With Profound Hypoxia
Performance testing of pulse oximeters. The protocol involves brief stable arterial oxygen desaturation in healthy volunteers and sampling arterial blood when a stable level of hypoxia has been attained.
- Trial name
- NCT04446247
- Testing
- Owlet Smart Sock Sensor 3rd Generation
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Owlet Baby Care, Inc.
Pulmonary Embolism, Thrombotic Disease
Study to Assess the Safety, Pharmacokinetics/Dynamics of DS-1040b in Subjects With Acute Submassive Pulmonary Embolism
This is a Phase 1b, double-blind (participants and Investigators), placebo-controlled, randomized, single-ascending dose, multi-center study to assess the safety, efficacy, tolerability, pharmacokinetics (PK), and…
- Trial name
- NCT02923115
- Testing
- DS-1040b, Enoxaparin
- Where
- 46 sites in United States, Austria and 6 more
- Volunteers
- 134 people
- Sponsor
- Daiichi Sankyo
Pulmonary Disease, Chronic Obstructive
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Dose-Response Relationship of Multiple Doses of GSK2269557 Administered as a Dry Powder to Chronic Obstructive Pulmonary Disease (COPD) Patients
This is a randomised, double-blind, placebo controlled, parallel group study to evaluate the safety, tolerability, pharmacokinetics and dose response of multiple doses of GSK2269557 administered as a dry powder in COPD subjects.
- Trial name
- NCT02130635
- Testing
- GSK2269557 100 MCG, GSK2269557 500 MCG
- Where
- 2 sites in Germany
- Volunteers
- 64 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
A Study To Assess Efficacy And Safety Of Different Doses Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
This study will assess the safety and efficacy of 5 doses GW642444 in subjects with Chonic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT00606684
- Testing
- GW642444 6.25, GW642444 3mcg, GW642444 12.5mcg
- Where
- 99 sites in United States, Argentina and 12 more
- Volunteers
- 602 people
- Sponsor
- GlaxoSmithKline
Small Cell Lung Cancer
BMS-986012 in Relapsed/Refractory SCLC
The purpose of this study is to determine the safety, tolerability, pharmacokinetics, immunogenicity, antitumor activity and pharmacodynamics of BMS-986012 alone and in combination with nivolumab in patients with…
- Trial name
- NCT02247349
- Testing
- BMS-986012 (anti-fucosyl-GM1), Nivolumab
- Where
- 16 sites in United States, Australia and 5 more
- Volunteers
- 106 people
- Sponsor
- Bristol-Myers Squibb
Sinusitis, Bacterial Infections
Study to Evaluate the Efficacy and Safety of Moxifloxacin Versus Amoxicillin/Clavulanate in the Treatment of Acute Bacterial Rhinosinusitis
This is a clinical study organized to collect clinical data to better define the activity of some antimicrobials already marketed in Italy and in the rest of the world for the treatment of acute bacterial rhinosinusitis
- Trial name
- NCT00493038
- Testing
- Moxifloxacin (Avelox, BAY12-8039), Amoxicillin/Clavulanate
- Where
- 34 sites in Italy
- Volunteers
- 293 people
- Sponsor
- Bayer
Asthma
Examining Changes in Nasal IL-1 During Acute Asthma Exacerbation in Adolescents
To study the change from baseline in IL-1β (interleukin 1 beta) concentrations in the nasal airway during acute asthma exacerbation, specifically to measure the degree of change and identify the timing of peak IL-1β…
- Trial name
- Attack Asthma (NCT04748055)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of North Carolina, Chapel Hill
Nasal Obstruction
The Vivaer Procedure for Treatment of the Septal Swell Bodies (SWELL)
Post-market study to access the clinical use of the Vivaer Arc Stylus to treat Septal Swell Bodies (SSB).
- Trial name
- SWELL (NCT05099263)
- Testing
- Vivaer Arc Stylus
- Where
- 9 sites in United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Aerin Medical
Influenza
Safety and Immunogenicity of the World Health Organization (WHO) Formulation of the 2004-2005 Fluzone® Vaccine
To observe and to describe the safety during Days 0 to 21 following injection of the 2004-2005 formulation of the inactivated, split-virion influenza vaccine Fluzone® in subjects aged 18-59 years and subjects aged ≥ 60 years.
- Trial name
- NCT00831987
- Testing
- Fluzone®: Influenza virus vaccine 2004-2005 formulation
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Chronic Obstructive Pulmonary Disease (COPD)
Study Comparing Dual Combination of Product (Budesonide and Formoterol) Given Via Two Different Inhalers. To See Which One Results in the Best Effect on Breathing.
Study comparing the same drugs as a dual combination product (budesonide and formoterol) given via two different inhalers. To see which one results in the best effect on breathing.
- Trial name
- NCT04078126
- Testing
- BFF, Symbicort Turbuhaler
- Where
- 4 sites in Germany
- Volunteers
- 35 people
- Sponsor
- AstraZeneca
Sarcopenia, Non Small Cell Lung Cancer
Prognostic Value of Sarcopenia and Nutritional Status in Early-stage Non-small Cell Lung Cancer
Growing evidence has confirmed that the prognosis of lung cancer is not only related to the stage of disease, but also to the physiological and psychological situation of the patients.
- Conditions
- Sarcopenia, Non Small Cell Lung Cancer, Malnutrition
- Trial name
- NCT05212285
- Testing
- Inbody 570, JAMAR Dynamometer, CT scan
- Where
- China
- Volunteers
- 469 people
- Sponsor
- Fudan University
Pulmonary Hypertension
Sedation With Dexmedetomidine During Cardiac Catheterization
Clinical dose escalation drug trial to evaluate the effect of 3 different doses of dexmedetomidine on the pulmonary vascular bed in pediatric subjects with elevated pulmonary vascular resistance (PVR).
- Trial name
- NCT01072643
- Testing
- Dexmedetomidine
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Aruna Nathan
Respiratory Syncytial Virus Infection
Effectiveness of Synagis (Palivizumab) Immunoprophylaxis in Preterm Infants With High Risk of Severe Respiratory Syncytial Virus (RSV) Infection
Published data by the Organización panamericana de la Salud shows that Peru's mortality rate from acute respiratory infections (ARI) in infants less than one year of life is second only to Haiti (14,150/100,000).
- Trial name
- INSPIRA (NCT01107535)
- Testing
- Synagis (palivizumab), monoclonal antibody for passive immunoprophylaxis against severe RSV disease administered according to usual clinical practice.
- Where
- 4 sites in Peru
- Volunteers
- 82 people
- Sponsor
- Abbott
Lung Cancer
Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer
The purpose of this study was to evaluate the efficacy and safety of the combination of nivolumab plus epacadostat in combination with platinum chemotherapy compared with platinum chemotherapy alone, in participants with…
- Trial name
- NCT03348904
- Testing
- Nivolumab, Epacadostat, Carboplatin
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Incyte Corporation
Pulmonary Disease, Chronic Obstructive, Pulmonary Emphysema
Longitudinal Follow up to Assess Biomarkers Predictive of Emphysema Progression in Patients With COPD (Chronic Obstructive Pulmonary Disease)
The study will include 60 healthy subjects (ex-smoker without any airflow limitation), 125 COPD GOLD (global initiative for chronic obstructive lung disease) I , 125 COPD GOLD II, 125 COPD GOLD III and up to 20 patients with COPD…
- Trial name
- NCT02719184
- Where
- 51 sites in United States, Belgium and 10 more
- Volunteers
- 463 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Pulmonary Arterial Hypertension
A Rising Single Dose Study of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics of MK-8892 (MK-8892-001)
This study will evaluate safety, tolerability and effects on central diastolic blood pressure (cDBP) of MK-8892 given as single oral doses in healthy male participants (Panel A and B) and in male participants with…
- Trial name
- NCT01798849
- Testing
- MK-8892
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Colonoscopy, Oxygenation
Comparison of Oxygenation and Ventilation With a Novel Nasal Mask Versus Standard of Care During Colonoscopy
Nasal continuous positive airway pressure (nCPAP) has been shown to effectively relieve upper airway obstruction in patients with OSA as it creates a pneumatic stent in the hypopharynx that reduces obstruction and allows for…
- Conditions
- Colonoscopy, Oxygenation, Ventilation
- Trial name
- NCT03139448
- Testing
- Oxygen via nasal cannula, Oxygen via SuperNO2VA nasal mask
- Where
- United States
- Volunteers
- 174 people
- Sponsor
- Vanderbilt University Medical Center
Influenza, Human
A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age
This is a study to assess the immune (antibody) response and safety of a Seqirus split virion, inactivated Quadrivalent Influenza Vaccine (Seqirus QIV), in comparison with a US licensed 2015/2016 Quadrivalent Influenza Vaccine…
- Trial name
- NCT02545543
- Testing
- Seqirus QIV, Comparator QIV
- Where
- 32 sites in United States
- Volunteers
- 2,278 people, healthy volunteers welcome
- Sponsor
- Seqirus
Nasal Congestion
Market Potential of Carbon Dioxide Nasal Spray
Carbon dioxide (CO2) is a naturally occurring gas that readily diffuses across body tissues and membranes. Data from earlier clinical studies conducted in 975 subjects with allergic rhinitis have shown that nasally administered…
- Trial name
- NCT02113449
- Testing
- Carbon Dioxide
- Where
- 4 sites in United States
- Volunteers
- 147 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Drug Utilization Study for Olodaterol
This study aims to characterise the use of single-agent olodaterol and single-agent indacaterol, the only marketed long-acting beta2-agonist (LABA)s authorised for chronic obstructive pulmonary disease (COPD), but not for asthma…
- Trial name
- NCT03030638
- Testing
- Olodaterol, Indacaterol
- Where
- 3 sites in Denmark, France and 1 more
- Volunteers
- 27,606 people
- Sponsor
- Boehringer Ingelheim
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.